The effect of a single administration of streptozotocin on hippocampus metabolites in NODSCID mice

The significant increase in the number of people diagnosed with diabetes mellitus in recent years makes studies of this problem topical. The persistent hyperglycemia accompanying the development and course of type 1 diabetes mellitus (T1DM) can affect the func-tional and structural levels of the organization of the central nervous system. These changes may be medi­ated by metabolic aberrations. Magnetic resonance spectroscopy (MRS) is a common method of intravital detection of metabolic reactions. In this study, MRS of the hippocampus of NOD.CB17-Prkdcscid/NcrCrl mice (NODSCID) was performed 4 days after the administration of streptozotocin (STZ) to assess the effect of STZ itself, and 60 days after the administration of STZ to another group of animals to assess the effect of chronic hyperglycemia caused by the delayed ef­fect of STZ, involving the death of pancreatic β-cells. The simulation of T1DM by STZ administration is used worldwide. Nevertheless, the question remains whether there is a short-term effect of the introduc­tion of STZ at the level of hippocampal metabolites recorded by MRS. The comparison of experimental and control animal groups revealed no effect of STZ on metabolites in the hippocampus of NODSCID mice on day 4 after its administration. In contrast, another comparison of the experimental and control animals on day 60 after STZ administration showed elevated contents of alanine and taurine, and a reduced lactate content. Thus, the introduction of STZ itself does not affect the metabolism of the hippocampus, and MRS is a promising method for assessing the effect of T1DM on brain metabolism in animals.

1. Lenzen S. The mechanisms of alloxanand streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216-226. DOI 10.1007/s00125007-0886-7.

2. Biessels G.J., Braun K.P., de Graaf R.A., van Eijsden P., Gispen W.H., Nicolay K. Cerebral metabolism in streptozotocin-diabetic rats: an in vivo magnetic resonance spectroscopy study. Diabetologia. 2001; 44:346-353. DOI 10.1007/s001250051625.

3. Lenzen S., Tiedge M., Panten U. Glucokinase in pancreatic B-cells and its inhibition by alloxan. Acta Endocrinol. 1987;115:21-29.

4. Duarte J.M., Carvalho R.A., Cunha R.A., Gruetter R. Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. J. Neurochem. 2009;111: 368-379. DOI 10.1111/j.1471-4159.2009.06349.x.

5. Lien Y.H., Shapiro J.I., Chan L. Effects of hypernatremia on organic brain osmoles. J. Clin. Invest. 1990;85(5):1427-1435. DOI 10.1172/ JCI114587.

6. Dufrane D., van Steenberghe M., Guiot Y., Goebbels R.M., Saliez A., Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006;15;81(1):36-45. DOI 10.1097/01.tp.0000189712.74495.82.

7. Lien Y.H., Shapiro J.I., Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J. Clin. Invest. 1991;88(1):303-309. DOI 10.1172/JCI115292.

8. Elsner M., Guldbakke B., Tiedge M., Munday R., Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia. 2000;43:1528-1533. DOI 10.1007/s001250051564.

9. Mangia S., Kumar A.F., Moheet A.A., Roberts R.J., Eberly L.E., Seaquist E.R., Tkáč I. Neurochemical profile of patients with type 1 diabetes measured by 1H-MRS at 4T. J. Cereb. Blood Flow Metab. 2013;33:754-759. DOI 10.1038/jcbfm.2013.13.

10. Geissler A., Frund R., Scholmerich J., Feuerbach S., Zietz B. Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. Exp. Clin. Endocrinol. Diabetes. 2003;111(7):421-427. DOI 10.1055/s-2003-44289.

11. Moshkin M.P., Akulov A.E., Petrovski D.V., Saik O.V., Petrovskiy E.D., Savelov A.A., Koptyug I.V. Proton magnetic resonance spectroscopy of brain metabolic shifts induced by acute administration of 2-deoxy-D-glucose and lipopolysaccharides. NMR Biomed. 2014;27:399-405. DOI 10.1002/nbm.3074.

12. Gruetter R. Automatic, localized in vivo adjustment of all first-and second-order shim coils. Magn. Reson. Med. 1993;29:804-811. DOI 10.1002/mrm.1910290613.

13. Northam E.A., Rankins D., Lin A., Wellard R.M., Pell G.S., Finch S.J., Werther G.A., Cameron F.J. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care. 2009;32:445-450. DOI 10.2337/dc08-1657.

14. Gurley S.B., Clare S.E., Snow K.P., Hu A., Meyer T.W., Coffman T.M. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. 2006;290(1):F214-F222. DOI 10.1152/ajprenal.00204. 2005.

15. Obrosova I.G., Fathallah L., Stevens M.J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp. Neurol. 2001;172(1):211-219. DOI 10.1006/exnr.2001.7789.

16. Heikkila O., Lundbom N., Timonen M., Groop P.H., Heikkinen S., Makimattila S. Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia. 2009;52:534-540. DOI 10.1007/s00125-0081242-2.

17. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993;30(6):672679. DOI 10.1002/mrm.1910300604.

18. Huber J.D., VanGilder R.L., Houser K.A. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am. J. Physiol. Heart Circ. Physiol. 2006;291(6):H2660-H2668. DOI 10.1152/ajpheart.00489.2006.

19. Qinna N.A., Badwan A.A. Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Des. Devel. Ther. 2015;9:2515-2525. DOI 10.2147/DDDT.S79885.

20. Hussy N., Deleuze C., Desarménien M.G., Moos F.C. Osmotic regulation of neuronal activity: a new role for taurine and glial cells in a hypothalamic neuroendocrine structure. Prog. Neurobiol. 2000; 62(2):113-134. DOI 10.1016/S0301-0082(99)00071-4.

21. Revsin Y., Rekers N.V., Louwe M.C., Saravia F.E., De Nicola A.F., de Kloet E.R., Oitzl M.S. Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in strepto¬zotocin-induced type 1 diabetes mice. Neuropsychopharmacology. 2009;34(3):747-758. DOI 10.1038/npp.2008.136.

22. Ito T., Schaffer S.W., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids. 2012;42(5): 1529-1539. DOI 10.1007/s00726-011-0883-5.

23. Rose S.J., Bushi M., Nagra I., Davies W.E. Taurine fluxes in insulin de¬pendent diabetes mellitus and rehydration in streptozotocin treated rats. Adv. Exp. Med. Biol. 2000;483:497-501. DOI 10.1007/0-30646838-755.

24. Jederstrom G., Grasjo J., Nordin A., Sjoholm I., Andersson A. Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes. Diabetes Technol. Ther. 2005; 7(6):948-957. DOI 10.1089/dia.2005.7.948.

25. Salceda R., Vilchis C., Coffe V., Hernandez-Munoz R. Changes in the redox state in the retina and brain during the onset of diabetes in rats. Neurochem. Res. 1998;23(6):893-897. DOI 10.1023/A:1022467230259.

26. King A.J. The use of animal models in diabetes research. Br. J. Pharmacol. 2012;166(3):877-894. DOI 10.1111/j.1476-5381.2012.01911.x.

27. Sandler S., Swenne I. Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia. 1983; 25(5):444-447.

28. Kreis R., Ross B.D. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. Radiology. 1992;184(1):123-130. DOI 10.1148/radiology.184.1.1319074.

29. Sarac K., Akinci A., Alkan A., Aslan M., Baysal T., Ozcan C. Brain metabolite changes on proton magnetic resonance spectroscopy in children with poorly controlled type 1 diabetes mellitus. Neuroradiology. 2005;47:562-565. DOI 10.1007/s00234-005-1387-3.

30. Lapidot A., Haber S. Effect of endogenous beta-hydroxybutyrate on glucose metabolism in the diabetic rabbit brain: A C-13-magnetic resonance spectroscopy study of [U-C-13] glucose metabolite. J. Neurosci. Res. 2001;64(2):207-216. DOI 10.1002/jnr.1067.

31. Schmidt R.E., Dorsey D.A., Beaudet L.N., Frederick K.E., Parvin C.A., Plurad S.B., Levisetti M.G. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 2003;163(5):20772091. DOI 10.1016/S0002-9440(10)63565-1.

32. Lenzen S. The mechanisms of alloxanand streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216-226. DOI 10.1007/s00125007-0886-7.

33. Schnedl W.J., Ferber S., Johnson J.H., Newgard C.B. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994;43(11):1326-1333. DOI 10.2337/diab.43.11.1326.

34. Lenzen S., Tiedge M., Panten U. Glucokinase in pancreatic B-cells and its inhibition by alloxan. Acta Endocrinol. 1987;115:21-29.

35. Sheshala R., Peh K.K., Darwis Y. Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery. Drug Dev. Ind. Pharm. 2009;35(11): 1364-1374. DOI 10.3109/03639040902939213.

36. Lien Y.H., Shapiro J.I., Chan L. Effects of hypernatremia on organic brain osmoles. J. Clin. Invest. 1990;85(5):1427-1435. DOI 10.1172/ JCI114587.

37. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001;50(6):537-546. DOI 10.1097/01.tp.0000189712.74495.82.

38. Lien Y.H., Shapiro J.I., Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J. Clin. Invest. 1991;88(1):303-309. DOI 10.1172/JCI115292.

39. Tanabe M., Nitta A., Ono H. Neuroprotection via strychnine-sensitive glycine receptors during post-ischemic recovery of excitatory synaptic transmission in the hippocampus. J. Pharmacol. Sci. 2010; 113(4):378-386. DOI 10.1254/jphs.10150FP.

40. Mangia S., Kumar A.F., Moheet A.A., Roberts R.J., Eberly L.E., Seaquist E.R., Tkáč I. Neurochemical profile of patients with type 1 diabetes measured by 1H-MRS at 4T. J. Cereb. Blood Flow Metab. 2013;33:754-759. DOI 10.1038/jcbfm.2013.13.

41. Terada T., Hara K., Haranishi Y., Sata T. Antinociceptive effect of in¬trathecal administration of taurine in rat models of neuropathic pain. Can. J. Anaesth. 2011;58(7):630-637. DOI 10.1007/s12630-0119504-8.

42. Moshkin M.P., Akulov A.E., Petrovski D.V., Saik O.V., Petrovskiy E.D., Savelov A.A., Koptyug I.V. Proton magnetic resonance spectroscopy of brain metabolic shifts induced by acute administration of 2-deoxy-D-glucose and lipopolysaccharides. NMR Biomed. 2014;27:399-405. DOI 10.1002/nbm.3074.

43. Timbrell J.A., Seabra V., Waterfield C.J. The in vivo and in vitro pro¬tective properties of taurine. Gen. Pharmacol. 1995;26(3):453-462. DOI 10.1016/0306-3623(94)00203-Y.

44. Northam E.A., Rankins D., Lin A., Wellard R.M., Pell G.S., Finch S.J., Werther G.A., Cameron F.J. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care. 2009;32:445-450. DOI 10.2337/dc08-1657.

45. van Harten B., de Leeuw F.E., Weinstein H.C., Scheltens P., Biessels G.J. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006;29:2539-2548. DOI 10.2337/dc061637.

46. Obrosova I.G., Fathallah L., Stevens M.J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp. Neurol. 2001;172(1):211-219. DOI 10.1006/exnr.2001.7789.

47. Wang W.T., Lee P., Yeh H.W., Smirnova I.V., Choi I.Y. Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo 1H MR spectroscopy at 9.4T. J. Neurochem. 2012;121:407-417. DOI 10.1111/j.1471-4159.2012.07698.x.

48. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993;30(6):672679. DOI 10.1002/mrm.1910300604.

49. Weiss R.B. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat. Rep. 1982;66:427-438.

50. Qinna N.A., Badwan A.A. Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Des. Devel. Ther. 2015;9:2515-2525. DOI 10.2147/DDDT.S79885.

51. Revsin Y., Rekers N.V., Louwe M.C., Saravia F.E., De Nicola A.F., de Kloet E.R., Oitzl M.S. Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in strepto¬zotocin-induced type 1 diabetes mice. Neuropsychopharmacology. 2009;34(3):747-758. DOI 10.1038/npp.2008.136.

52. Rose S.J., Bushi M., Nagra I., Davies W.E. Taurine fluxes in insulin de¬pendent diabetes mellitus and rehydration in streptozotocin treated rats. Adv. Exp. Med. Biol. 2000;483:497-501. DOI 10.1007/0-30646838-755.

53. Salceda R., Vilchis C., Coffe V., Hernandez-Munoz R. Changes in the redox state in the retina and brain during the onset of diabetes in rats. Neurochem. Res. 1998;23(6):893-897. DOI 10.1023/A:1022467230259.

54. Sandler S., Swenne I. Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia. 1983; 25(5):444-447.

55. Sarac K., Akinci A., Alkan A., Aslan M., Baysal T., Ozcan C. Brain metabolite changes on proton magnetic resonance spectroscopy in children with poorly controlled type 1 diabetes mellitus. Neuroradiology. 2005;47:562-565. DOI 10.1007/s00234-005-1387-3.

56. Schmidt R.E., Dorsey D.A., Beaudet L.N., Frederick K.E., Parvin C.A., Plurad S.B., Levisetti M.G. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 2003;163(5):20772091. DOI 10.1016/S0002-9440(10)63565-1.

57. Schnedl W.J., Ferber S., Johnson J.H., Newgard C.B. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994;43(11):1326-1333. DOI 10.2337/diab.43.11.1326.

58. Sheshala R., Peh K.K., Darwis Y. Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery. Drug Dev. Ind. Pharm. 2009;35(11): 1364-1374. DOI 10.3109/03639040902939213.

59. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001;50(6):537-546. DOI 10.1097/01.tp.0000189712.74495.82.

60. Tanabe M., Nitta A., Ono H. Neuroprotection via strychnine-sensitive glycine receptors during post-ischemic recovery of excitatory synaptic transmission in the hippocampus. J. Pharmacol. Sci. 2010; 113(4):378-386. DOI 10.1254/jphs.10150FP.

61. Terada T., Hara K., Haranishi Y., Sata T. Antinociceptive effect of in¬trathecal administration of taurine in rat models of neuropathic pain. Can. J. Anaesth. 2011;58(7):630-637. DOI 10.1007/s12630-0119504-8.

62. Timbrell J.A., Seabra V., Waterfield C.J. The in vivo and in vitro pro¬tective properties of taurine. Gen. Pharmacol. 1995;26(3):453-462. DOI 10.1016/0306-3623(94)00203-Y.

63. van Harten B., de Leeuw F.E., Weinstein H.C., Scheltens P., Biessels G.J. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006;29:2539-2548. DOI 10.2337/dc061637.

64. Wang W.T., Lee P., Yeh H.W., Smirnova I.V., Choi I.Y. Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo 1H MR spectroscopy at 9.4T. J. Neurochem. 2012;121:407-417. DOI 10.1111/j.1471-4159.2012.07698.x.

65. Weiss R.B. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat. Rep. 1982;66:427-438.